Sarah Jenkins, MD
Medical Oncology · Knoxville, TNNPI 1124481775
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.6%), other and education — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Novartis at 51.4% of the total. That places this record below the midpoint for medical oncology clinicians in TN, where the typical reported total is $6,231.
Across 158 payments — averaging $31.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Merck$361
- Gilead$356
- Daiichi Sankyo Inc.$240
- AstraZeneca$200
- Pfizer$134
- plus $1K from 30 others
Across 2 payments — averaging $5976.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Food & beverage$2,58353%
- Education$1453%
- Other$2,18044%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 40 | $2,522 |
| Merck | 18 | $361 |
| Gilead(2 entities) | 20 | $356 |
| Daiichi Sankyo Inc. | 12 | $240 |
| AstraZeneca | 6 | $200 |
| Pfizer | 8 | $134 |
| Seagen Inc. | 7 | $131 |
| AVEO Pharmaceuticals, Inc. | 2 | $104 |
| Astellas Pharma US Inc | 4 | $97 |
| Johnson & Johnson(2 entities) | 4 | $70 |
| AbbVie | 3 | $65 |
| Genentech USA, Inc. | 4 | $60 |
| Puma Biotechnology, Inc. | 3 | $46 |
| Sanofi | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Caris MPI, Inc. | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Springworks Therapeutics, Inc. | 1 | $32 |
| Acrotech Biopharma Inc. | 1 | $27 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Tempus AI, Inc | 1 | $24 |
| Incyte Corporation | 1 | $22 |
| Rigel Pharmaceuticals, Inc. | 1 | $21 |
| Amgen | 1 | $19 |
| Immunocore Limited | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Aadi Bioscience, Inc. | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $14 |
| Deciphera Pharmaceuticals Inc. | 1 | $14 |
| Exelixis Inc. | 1 | $14 |
How this compares
$4,908 in reported general payments places this provider in the 40th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 29 | $428,452 |
| EliquisApixaban | 25 | $17,693 |
| Exemestane | 26 | $3,910 |
| Anastrozole | 107 | $2,087 |
| Dexamethasone | 24 | $747 |
| Ondansetron Hcl | 49 | $737 |
| Tamoxifen Citrate | 32 | $555 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $550 |
| Oxycodone Hcl | 15 | $364 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 22 | $280 |
| Letrozole | 15 | $256 |
| Duloxetine Hcl | 15 | $197 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $134 | $17,69325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 101 medical oncology providers in Tennessee.
Other medical oncology in Knoxville
- David ChismKnoxville$45K
- Tracy DobbsKnoxville$26K
- Timothy PanellaKnoxville$13K
- James DavidsonKnoxville$8K
- William PaoNashville$838K
- Gregory VidalGermantown$360K
- Dana ThompsonNashville$339K
- Robert RamirezNashville$321K
- Mace RothenbergNashville$318K
- Melissa JohnsonNashville$290K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.